Replies to post #216 on Corvus Pharmaceuticals Inc (CRVS)

[kenyonn2000]

I agree. I think we have one last major hurdle to go, and it's those new ALC>900 patients on study right now. They need to confirm that kind of initial response rate. If they do, and side effects remain low, we've got a clear runway for an orphan drug designation and fast track status for a registration trial in refractory PTCL--likely early next year. And then they look at frontline in subtypes most likely to respond. By then, I hope they have raised enough money at much higher prices (or have landed a partnership) that it allows them to explore 818 in autoimmune.